Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brookfield Infrastructure Partners LP (BIP) vs Nuvalent Inc (NUVL) Price & Performance

Brookfield Infrastructure Partners LPTrade
Nuvalent IncTrade

Price performance (Past 24H)

Key statistics

Brookfield Infrastructure Partners LP vs Nuvalent Inc — how do they compare? Brookfield Infrastructure Partners LP trades at $38.19 (market cap $17.38B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Brookfield Infrastructure Partners LP is the larger of the two by market cap, and Brookfield Infrastructure Partners LP pays a 4.77% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.

BIPNUVL
Market Cap
$17.38B$9.81B
Sector
IndustrialsTechnology
52-Week High
$40.08$123.96
52-Week Low
$29.81$72.16
Enterprise Value
$79.06B$8.52B
Dividend Yield
4.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Brookfield Infrastructure Partners LP

Brookfield Infrastructure Partners (BIP) trades at $37.61, down slightly by 0.11% today. The stock shows bullish technical signals with strong analyst support (81% buy ratings) and a $45.50 consensus price target. Recent earnings have been mixed with one beat and two misses, but the company maintains robust cash flows with $5.97B from operations in 2025. BIP offers a 5% dividend yield with recent H1-26 payment of $0.46 per share.

BIP presents a compelling value opportunity with discounted valuation metrics (P/S 0.73, EV/EBITDA 7.55) and strong infrastructure assets. However, investors face risks from recent earnings volatility, high P/E ratio of 57.8, and declining profit margins. The company's global infrastructure portfolio provides inflation protection and stable cash flows, supporting the bullish analyst consensus despite near-term headwinds.

Nuvalent Inc

Nuvalent (NUVL) trades at $123.94, showing minimal daily movement with a 0.03% gain. The stock is in focus following GSK's proposed acquisition at $124 per share, announced June 2026. Technically, the price is at the acquisition offer level with a bullish moving average signal but overbought RSI readings. Fundamentally, the company reports significant losses with negative ROE and ROA, while cash flow remains supported by financing activities.

The investment outlook is dominated by the pending acquisition, limiting upside beyond the offer price. Key risks include deal completion uncertainty and ongoing operational losses. Analyst sentiment is mixed with a slight hold bias, reflecting caution until transaction closure. Shareholder value hinges on successful deal execution amid financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Brookfield Infrastructure Partners LP

Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.

Read more on BIP

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.

Read more on NUVL